An interview with Bayer's Bernardo Kanahuati, senior vice president, global head cardiorenal and product team lead, Kerendia, and Katja Rohwedder, senior medical affairs physician, global medical ...

– Initiating Phase 2 trial to evaluate lorundrostat for the treatment of patients with moderate-to-severe obstructive sleep apnea (OSA) and hypertension – ...

The European Commission (EC) has granted marketing authorisation to BridgeBio Pharma’s selective small molecule, acoramidis, ...

PALO ALTO, CA, USA I 11, 2025 I BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused ...

BURLINGTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient ...

A recent modeling study has identified risk factors predictive of good and bad outcomes in non-diabetic CKD, such as gender, ...

The following is a summary of “Association between triglyceride-glucose index and its composite obesity indexes and cardio-renal disease: analysis of the NHANES 2013-2018 cycle,” published in the ...

More than 35 million people in the U.S. have chronic kidney disease (CKD), a condition in which the kidneys are damaged and can't do their job efficiently. "Your kidneys filter the total blood in the ...

George Medicines appoints Amy Carroll as Senior Vice President of Medical AffairsLondon, UK, 3 February 2025 – George Medicines, a late-stage ...

Biomarkers can provide insights into underlying mechanisms and lead to a better understanding of complex disease states such as the cardiorenal syndrome, which can lead to better therapies and ...

The first kidney or cardiorenal outcome trial with an SGLT2 inhibitor, CREDENCE, was done in patients with type 2 diabetes, mostly because canagliflozin (Invokana, Janssen) was already on the ...

DENVER, Jan. 22, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of ...